Progressive stent technologies: new approaches for the treatment of cardiovascular diseases

Bibliography

• STONE GW, ELLIS SG, COX DA et al.: One-year clinical results with the slow-release, polymer-based, paclitaxel-eluting TAXUS stent: the TAXUS-IV trial. Circulation (2004) 109(16):1942-1947.
   PubMed Web of Science ®Google Scholar
• MORICE MC, SERRUYS PW, SOUSA JE et al.: A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N. Engl. J. Med. (2002) 346(23):1773-1780.
   PubMed Web of Science ®Google Scholar
• KUCHULAKANTI PK, CHU WW, TORGUSON R et al.: Correlates and long-term outcomes of angiographically proven stent thrombosis with sirolimus- and paclitaxel-eluting stents. Circulation (2006) 113(8):1108-1113.
   PubMed Web of Science ®Google Scholar
• IAKOVOU I, SCHMIDT T, BONIZZONI E et al.: Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA (2005) 293(17):2126-2130.
   PubMed Web of Science ®Google Scholar
• ONG AT, HOYE A, AOKI J et al.: Thirty-day incidence and six-month clinical outcome of thrombotic stent occlusion after bare-metal, sirolimus, or paclitaxel stent implantation. J. Am. Coll. Cardiol. (2005) 45(6):947-953.
   PubMed Web of Science ®Google Scholar
• ONG AT, MCFADDEN EP, REGAR E et al.: Late angiographic stent thrombosis (LAST) events with drug-eluting stents. J. Am. Coll. Cardiol. (2005) 45(12):2088-2092.
   PubMed Web of Science ®Google Scholar
• HOYE A, IAKOVOU I, GE L et al.: Long-term outcomes after stenting of bifurcation lesions with the ‘crush’ technique: predictors of an adverse outcome. J. Am. Coll. Cardiol. (2006) 47(10):1949-1958.
   PubMed Web of Science ®Google Scholar
• SMITH SC Jr, FELDMAN TE, HIRSHFELD JW Jr et al.: ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update 2001 Guidelines for Percutaneous Coronary Intervention). Circulation (2006) 113(7):e166-e286.
   PubMedGoogle Scholar
• KASTRATI A, DIBRA A, MEHILLI J et al.: Predictive factors of restenosis after coronary implantation of sirolimus- or paclitaxel-eluting stents. Circulation (2006) 113(19):2293-2300.
   PubMed Web of Science ®Google Scholar
• KIM YH, PARK SW, HONG MK et al.: Comparison of simple and complex stenting techniques in the treatment of unprotected left main coronary artery bifurcation stenosis. Am. J. Cardiol. (2006) 97(11):1597-1601.
   PubMed Web of Science ®Google Scholar
• MEHILLI J, DIBRA A, KASTRATI A et al.: Randomized trial of paclitaxel- and sirolimus-eluting stents in small coronary vessels. Eur Heart J. (2006) 27(3):260-266.
   PubMed Web of Science ®Google Scholar
• HOYE A, TANABE K, LEMOS PA et al.: Significant reduction in restenosis after the use of sirolimus-eluting stents in the treatment of chronic total occlusions. J. Am. Coll. Cardiol. (2004) 43(11):1954-1958.
   PubMed Web of Science ®Google Scholar
• GE L, IAKOVOU I, COSGRAVE J et al.: Immediate and mid-term outcomes of sirolimus-eluting stent implantation for chronic total occlusions. Eur. Heart J. (2005) 26(11):1056-1062.
   PubMed Web of Science ®Google Scholar
• MEREDITH I, ORMISTON J, WHITBOURN R et al.: First-in-human study of the Endeavor ABT-578-eluting phosphorylcholine-encapsulated stent system in de novo native coronary artery lesions: Endeavor I Trial. EuroIntervention (2005) 1:157-164.
   PubMedGoogle Scholar
• MEREDITH I, WIJNS W: ENDEAVOR I and II clinical program. Long term follow-up. European Society of Cardiology Congress. Stockholm, Sweden (4 September 2005).
   Google Scholar
• KANDZARI DE: Overview of ABT-578/PC/Cobalt technology and clinical trial program. 55th Annual Scientific Session of the American College of Cardiology. Atlanta, GA, USA (11 – 16 March 2006).
   Google Scholar
• KANDZARI DE, LEON MB: ENDEAVOR III. A randomized trial to confirm the safety and efficacy of the medtronic zotarolimus eluting stent in de novo native coronary artery lesions. 17th Transcatheter Cardiovascular Therapeutics Scientific Symposium. Washington, DC, USA (16 – 21 October 2005).
   Google Scholar
• ABIZAID A, LANSKY A, FITZGERALD P et al.: Percutaneous coronary revascularization using a trilayer phosphorylocholine-coated zotarolimus-eluting stent: the ZoMaxx IVUS trial. 55th Annual Scientific Session of the American College of Cardiology. Atlanta, GA, USA (11 – 16 March 2006).
   Google Scholar
• HONG MK, MINTZ GS, LEE CW et al.: Late stent malapposition after drug-eluting stent implantation: an intravascular ultrasound analysis with long-term follow-up. Circulation (2006) 113(3):414-419.
   PubMed Web of Science ®Google Scholar
• YEUNG AC: The Zomaxx Trials. 55th Annual Scientific Session of the American College of Cardiology. Atlanta, GA, USA (11 – 16 March 2006).
   Google Scholar
• SERRUYS PW, ONG ATL, PIEK JJ et al.: A randomized comparison of a durable polymer Everolimus-eluting stent with a bare metal coronary stent: the SPIRIT first trial. EuroIntervention (2005) 1(1):58-69.
   PubMedGoogle Scholar
• TSUCHIDA K, PIEK JJ, NEUMANN FJ et al.: One-year results of a durable polymer everolimus-eluting stent in de novo coronary narrowings (The SPIRIT FIRST Trial). EuroIntervention (2005) 1:266-272.
   PubMedGoogle Scholar
• STEPKOWSKI SM: Molecular targets for existing and novel immunosuppressive drugs. Expert Rev. Mol. Med. (2000) 2000:1-23.
   PubMedGoogle Scholar
• KIPSHIDZE N, DANGAS G, TSAPENKO M et al.: Role of the endothelium in modulating neointimal formation: vasculoprotective approaches to attenuate restenosis after percutaneous coronary interventions. J. Am. Coll. Cardiol. (2004) 44(4):733-739.
   PubMed Web of Science ®Google Scholar
• WERNER N, JUNK S, LAUFS U et al.: Intravenous transfusion of endothelial progenitor cells reduces neointima formation after vascular injury. Circ. Res. (2003) 93(2):e17-e24.
   PubMed Web of Science ®Google Scholar
• AOKI J, SERRUYS PW, VAN BEUSEKOM H et al.: Endothelial progenitor cell capture by stents coated with antibody against CD34: the HEALING-FIM (Healthy Endothelial Accelerated Lining Inhibits Neointimal Growth-First In Man) registry. J. Am. Coll. Cardiol. (2005) 45(10):1574-1579.
   PubMed Web of Science ®Google Scholar
• SKETCH MH Jr, BALL M, RUTHERFORD B et al.: Evaluation of the Medtronic (Driver) cobalt-chromium alloy coronary stent system. Am. J. Cardiol. (2005) 95(1):8-12.
   PubMed Web of Science ®Google Scholar
• DUCKERS E: Endothelial progenitor cell capture (EPC): update and perspectives. EuroPCR. Paris, France (24 – 27 May 2005).
   Google Scholar
• LIU X, HUANG Y, HANET C et al.: Study of antirestenosis with the BiodivYsio dexamethasone-eluting stent (STRIDE): a first-in-human multicenter pilot trial. Catheter Cardiovasc. Interv. (2003) 60(2):172-178; discussion 179.
   PubMed Web of Science ®Google Scholar
• DE SCHEERDER I: The Abbott vascular devices dexamethasone eluting stent: from STRIDE to the ‘real-world’ SAFE registry. Transcatheter Therapeutics Scientific Sessions, Washington, DC, USA (2003).
   Google Scholar
• LEFER AM, SCALIA R, LEFER DJ: Vascular effects of HMG CoA-reductase inhibitors (statins) unrelated to cholesterol lowering: new concepts for cardiovascular disease. Cardiovasc. Res. (2001) 49(2):281-287.
   PubMed Web of Science ®Google Scholar
• INDOLFI C, CIOPPA A, STABILE E et al.: Effects of hydroxymethylglutaryl coenzyme A reductase inhibitor simvastatin on smooth muscle cell proliferation in vitro and neointimal formation in vivo after vascular injury. J. Am. Coll. Cardiol. (2000) 35(1):214-221.
   Google Scholar
• TANABE K, ISHIYAMA H, VAN DER GIESSEN W, SERRUYS PW: Terumo statin releasing stent (preclinical results). In: Drug-Eluting Stents. Gershlick A (Ed.), Taylor and Francis Group, London, UK (2005):313-321.
   Google Scholar
• HEUBLEIN B, ROHDE R, KAESE V et al.: Biocorrosion of magnesium alloys: a new principle in cardiovascular implant technology? Heart (2003) 89(6):651-656.
   PubMed Web of Science ®Google Scholar
• VAN DER GIESSEN WJ, LINCOFF AM, SCHWARTZ RS et al.: Marked inflammatory sequelae to implantation of biodegradable and nonbiodegradable polymers in porcine coronary arteries. Circulation (1996) 94(7):1690-1697.
   PubMed Web of Science ®Google Scholar
• DI MARIO C, GRIFFITHS H, GOKTEKIN O et al.: Drug-eluting bioabsorbable magnesium stent. J. Interv. Cardiol. (2004) 17(6):391-395.
   PubMedGoogle Scholar
• ERBEL R: Coronary results of the first absorbable metal stent: The Progress-I trial. 55th Annual Scientific Session of the American College of Cardiology. Atlanta, GA, USA (11 – 16 March 2006).
   Google Scholar
• SERRUYS PW: Emerging technology 1. Stents – new drugs. 55th Annual Scientific Session of ACC, Atlanta, GA, USA, 11 – 14 March (2006).
   Google Scholar
• MIDDLETON J, TIPTON A: Synthetic biodegradable polymers as orthopedic devices. Biomaterials (2000) 21(23):2335-2346.
   PubMed Web of Science ®Google Scholar
• VOGT F, STEIN A, RETTEMEIER G et al.: Long-term assessment of a novel biodegradable paclitaxel-eluting coronary polylactide stent. Eur. Heart J. (2004) 25(15):1330-1340.
   PubMed Web of Science ®Google Scholar
• TAMAI H, IGAKI K, KYO E et al.: Initial and 6-month results of biodegradable poly-l-lactic acid coronary stents in humans. Circulation (2000) 102(4):399-404.
   PubMed Web of Science ®Google Scholar
• GRUBE E, HAUPTMANN KE, BUELLESFELD L, LIM V, ABIZAID A: Six-month results of a randomized study to evaluate safety and efficacy of a Biolimus A9™ eluting stent with a biodegradable polymer coating. EuroIntervention (2005) 1:53-57.
   PubMedGoogle Scholar
• COSTA RA, LANSKY AJ, MINTZ GS et al.: Angiographic results of the first human experience with everolimus-eluting stents for the treatment of coronary lesions (the FUTURE I trial). Am. J. Cardiol. (2005) 95(1):113-116.
   PubMed Web of Science ®Google Scholar
• GRUBE E, SONODA S, IKENO F et al.: Six- and twelve-month results from first human experience using everolimus-eluting stents with bioabsorbable polymer. Circulation (2004) 109(18):2168-2171.
   PubMed Web of Science ®Google Scholar
• GRUBE E: FUTURE II: Multicenter evaluation of the bioabsorbable polymer-based everolimus-eluting stent. 15th Annual Transcatheter Cardiovascular Therapeutics. Washington, DC, USA (15 – 19 September 2003).
   Google Scholar
• GAMBHIR DS: The Infinnium polymer-based paclitaxel drug-eluting stent: Results from real world clinical trials SIMPLE 1 and SIMPLE 2. Transcatheter Cardiovascular Therapeutics 2004. Washington, DC, USA (22 October 2004).
   Google Scholar
• LELE S: Heparin sirolimus stent. EuroPCR 2006. Paris, France (16 – 19 May 2006).
   Google Scholar
• SERRUYS PW, SIANOS G, ABIZAID A et al.: The effect of variable dose and release kinetics on neointimal hyperplasia using a novel paclitaxel-eluting stent platform: the Paclitaxel In-Stent Controlled Elution Study (PISCES). J. Am. Coll. Cardiol. (2005) 46(2):253-260.
   PubMed Web of Science ®Google Scholar
• AOKI J, ONG AT, ABIZAID A et al.: One-year clinical outcome of various doses and pharmacokinetic release formulations of paclitaxel eluted from an erodable polymer. Insight in the Paclitaxel In-Stent Controlled Elution Study (PISCES). EuroIntervention (2005) 2:165-172.
   Google Scholar
• KAUL U: Erodablepolymer-reservoir paclitaxel drug eluting stents II: cobalt chromium platforms in complex lesionsTranscatheter Cardiovascular Therapeutics 2004. Washington, DC, USA (22 October 2004).
   Google Scholar
• SERRUYS PW: The new CoStarTM stent: 12 month results with the new DES technology. EuroPCR. Paris, France (24 – 27 May 2005).
   Google Scholar
• WIJNS W: CoStar™ Paclitaxel-eluting stent: relevance in drug-eluting stent clinical data landscape. EuroPCR 2006. Paris, France (16 – 19 May 2006).
   Google Scholar
• DAWKINS K: The Eurostar trial. EuroPCR. Paris, France (24 – 27 May 2005).
   Google Scholar
• GERSHLICK A, DE SCHEERDER I, CHEVALIER B et al.: Inhibition of restenosis with a paclitaxel-eluting, polymer-free coronary stent: the European evaLUation of pacliTaxel Eluting Stent (ELUTES) trial. Circulation (2004) 109(4):487-493.
   PubMed Web of Science ®Google Scholar
• PARK SJ, SHIM WH, HO DS et al.: A paclitaxel-eluting stent for the prevention of coronary restenosis. N. Engl. J. Med. (2003) 348(16):1537-1545.
   PubMed Web of Science ®Google Scholar
• LANSKY AJ, COSTA RA, MINTZ GS et al.: Non-polymer-based paclitaxel-coated coronary stents for the treatment of patients with de novo coronary lesions: angiographic follow-up of the DELIVER clinical trial. Circulation (2004) 109(16):1948-1954.
   PubMed Web of Science ®Google Scholar
• VIRMANI R: Atrium medical bioabsorbable oil based delivery of a sirolimus analogue from a stent and balloon. Transcatheter Cardiovascular Therapeutics 2005. Washington, DC, USA (17 – 21 October 2005).
   Google Scholar
• WINDECKER S, MAYER I, DE PASQUALE G et al.: Stent coating with titanium-nitride-oxide for reduction of neointimal hyperplasia. Circulation (2001) 104(8):928-933.
   PubMed Web of Science ®Google Scholar
• WINDECKER S, SIMON R, LINS M et al.: Randomized comparison of a titanium-nitride-oxide-coated stent with a stainless steel stent for coronary revascularization: the TiNOX trial. Circulation (2005) 111(20):2617-2622.
   PubMed Web of Science ®Google Scholar
• WIENEKE H, DIRSCH O, SAWITOWSKI T et al.: Synergistic effects of a novel nanoporous stent coating and tacrolimus on intima proliferation in rabbits. Catheter Cardiovasc. Interv. (2003) 60(3):399-407.
   PubMed Web of Science ®Google Scholar
• KOLLUM M, FARB A, SCHREIBER R et al.: Particle debris from a nanoporous stent coating obscures potential antiproliferative effects of tacrolimus-eluting stents in a porcine model of restenosis. Catheter Cardiovasc. Interv. (2005) 64(1):85-90.
   PubMed Web of Science ®Google Scholar
• GERCKENS U, BUELLESFELD L, HORSKOTTE D et al.: Evaluation of a tacrolimus-eluting coronary stent with nanoporous ceramic coating in treatment of native coronary artery lesions: Phase I and II of the PRESENT study. J. Am. Coll. Cardiol. (2003) 41(Suppl. A):7A.
   Google Scholar
• HAUSLEITER J, KASTRATI A, WESSELY R et al.: Prevention of restenosis by a novel drug-eluting stent system with a dose-adjustable, polymer-free, on-site stent coating. Eur. Heart J. (2005) 26(15):1475-1481.
   PubMed Web of Science ®Google Scholar
• MORICE MC, BESTEHORN HP, CARRIE D et al.: Direct stenting of the de novo coronary stenoses with tacrolimus-eluting versus carbon-coated carbostents. The randomized JUPITER II trial. EuroIntervention (2006) 2:45-52.
   PubMedGoogle Scholar
• MCFADDEN EP, STABILE E, REGAR E et al.: Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy. Lancet (2004) 364(9444):1519-1521.
   PubMed Web of Science ®Google Scholar
• NEBEKER JR, VIRMANI R, BENNETT CL et al.: Hypersensitivity cases associated with drug-eluting coronary stents: a review of available cases from the Research on Adverse Drug Events and Reports (RADAR) project. J. Am. Coll. Cardiol. (2006) 47(1):175-181.
   PubMed Web of Science ®Google Scholar
• SAIA F, LEMOS PA, ARAMPATZIS CA et al.: Routine sirolimus eluting stent implantation for unselected in-stent restenosis: insights from the rapamycin eluting stent evaluated at Rotterdam Cardiology Hospital (RESEARCH) registry. Heart (2004) 90(10):1183-1188.
   PubMed Web of Science ®Google Scholar
• NEUMANN FJ, DESMET W, GRUBE E et al.: Effectiveness and safety of sirolimus-eluting stents in the treatment of restenosis after coronary stent placement. Circulation (2005) 111(16):2107-2111.
   PubMed Web of Science ®Google Scholar
• KASTRATI A, MEHILLI J, VON BECKERATH N et al.: ISAR-DESIRE: drug-eluting stents for in-stent restenosis. European Society of Cardiology Congress. Munich, Germany (28 August – 1 September 2004).
   Google Scholar
• LEMOS PA, HOYE A, GOEDHART D et al.: Clinical, angiographic, and procedural predictors of angiographic restenosis after sirolimus-eluting stent implantation in complex patients: an evaluation from the Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) study. Circulation (2004) 109(11):1366-1370.
   PubMed Web of Science ®Google Scholar
• COLOMBO A, MOSES JW, MORICE MC et al.: Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions. Circulation (2004) 109(10):1244-1249.
   PubMed Web of Science ®Google Scholar
• SHARMA SK: Simultaneous kissing drug-eluting stent technique for percutaneous treatment of bifurcation lesions in large-size vessels. Catheter Cardiovasc. Interv. (2005) 65(1):10-16.
   PubMed Web of Science ®Google Scholar
• NAKAMURA S, MUTHUSAMY TS, BAE JH et al.: Impact of sirolimus-eluting stent on the outcome of patients with chronic total occlusions. Am. J. Cardiol. (2005) 95(2):161-166.
   PubMed Web of Science ®Google Scholar
• WERNER GS, KRACK A, SCHWARZ G et al.: Prevention of lesion recurrence in chronic total coronary occlusions by paclitaxel-eluting stents. J. Am. Coll. Cardiol. (2004) 44(12):2301-2306.
   PubMed Web of Science ®Google Scholar
• SERRUYS PW, ONG AT, COLOMBO A et al.: Arterial revascularization therapies study part II: sirolimus-eluting stents for the treatment of patients with multivessel de novo coronary artery lesions. 54th American College of Cardiology Annual Scientific Session. Orlando, FL, USA (6 March 2005).
   Google Scholar
• KAPUR A, MALIK IS, BAGGER JP et al.: The Coronary Artery Revascularisation in Diabetes (CARDia) trial: background, aims, and design. Am. Heart J. (2005) 149(1):13-19.
   PubMed Web of Science ®Google Scholar
• ONG AT, SERRUYS PW, MOHR FW et al.: The Synergy Between Percutaneous Coronary Intervention with TAXus™ and Cardiac Surgery (SYNTAX) Study: design, rationale and run-in phase. Am. Heart J. (2006). 151(6):1194-1204.
   PubMed Web of Science ®Google Scholar
• SERRUYS PW: Drug-eluting stents: results from clinical trials. The PISCES trials. 55th Annual Scientific Session of the American College of Cardiology. Atlanta, GA, USA (11 – 16 March 2006).
   Google Scholar